Integrative genomic analysis data from TCGA suggest that AMLDNMT3A/FLT3/NPM1 is a unique disease subset with distinctive features at the mRNA, miRNA, and epigenetic levels, but the clinical features and outcome characteristics of this AML subset remain unknown. Here, FLT3 is linked to acute myeloid leukemia.